HARBIN, China, April 2, 2008 /Xinhua-PRNewswire-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (OTC Bulletin Board: RHGP) ("Renhuang" or "the Company"), a leading pharmaceutical company in China, today announced that one of its four main traditional Chinese medicine products, Tianma pills, a headache treatment, has been recognized as an advanced technology product by the Science and Technology Institute of Heilongjiang, China.
Using Renhuang's advanced technology, Tianma pills hold a higher concentration of the main active ingredient, resulting in a higher curative effect compared to the competing products. Rhizoma gastrodiae, the main active ingredient of Tianma pills, functions as a painkiller and has been used to treat headaches for over 1,000 years. Tianma Pills, introduced in the market in early 2006, are sold to hospitals and drug stores throughout China.
The Science and Technology Institute of Heilongjiang is a government supported entity which promotes the development of high technology companies and technologically advanced products. The "advanced technology product" title is given to products considered superior to competing products in the same class.
"Renhuang is honored to receive this prestigious award for Tianma Pills from the Science and Technology Institute of Heilongjiang," said Mr. Shaoming Li, Renhuang's Chairman & CEO. "We will continue to improve our products using our strong research and development capability and advanced technology, and expect to seize additional market share by focusing on the development of novel products."
About Renhuang Pharmaceuticals, Inc.
Founded in 1996, Renhuang Pharmaceuticals, Inc., produces Western and traditional Chinese medicines (TCM), and branded pharmaceuticals, using its GMP-certified facilities in China. The Company's GMP-certified manufacturing facilities, containing cutting-edge technologies and advanced equipment, are capable of producing as many as 200 types of pharmaceuticals. Additionally, Renhuang distributes raw materials and finished pharmaceuticals using its broad distribution channels and third party distributors throughout China. The Company's distribution network includes over 3,000 sales representatives in 70 sales centers across 24 districts, covering over 50% of the greater China. The Company also exports its products to Russia and Southeast Asia. For more information, visit http://www.renhuang.com .
Safe Harbor Statement
This press release contains certain statements that may include
'forward-looking statements' as defined in the Securities Act of 1933, and the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein are 'forward-looking statements'. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with and available from the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For more information, please contact:
Renhuang Pharmaceuticals, Inc.
Ms. Shuang Tan, IR Contact
Tel: +86-451-5392-5461
Email: ir@renhuang.com
CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
